Single Chain Trimer Molecules for Rapid CD8+ T Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding antigen-specific CD8+ T cells for therapeutic use, such as adoptive T cell immunotherapy, are time-consuming and inefficient, requiring months to generate sufficient numbers, and lack effective enrichment for antigen-specific responses.
Innovation Solution
The development of single chain trimer (SCT) molecules comprising an antigen peptide, β2-microglobulin, and a class I heavy chain, which can be used to rapidly expand antigen-specific CD8+ T cells through a two-step culture process, achieving significant enrichment and expansion in less than two months.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional expansion methods (REM, anti-CD3/anti-CD28) are used to generate sufficient numbers of antigen-specific CD8+ T cells, then the quantity of T cells can be increased to therapeutic levels, but the time required for expansion increases to 3-4 months
Solution Approach 1:
The patent introduces a modified anti-CD3 monoclonal antibody that recognizes both CD3 and the Fc region of the antibody itself, creating a self-crosslinking mechanism. This intermediary molecular design enables simultaneous T cell activation and signal amplification without requiring prolonged culture periods, reducing expansion time from 3-4 months to 2-3 weeks while achieving therapeutic cell numbers
Solution Approach 2:
The invention changes the binding parameters of the anti-CD3 monoclonal antibody by engineering it to recognize an epitope that includes the Fc region. This parameter modification allows the antibody to bind with higher avidity and create self-crosslinks, fundamentally altering the activation kinetics and enabling rapid T cell expansion in a shortened culture period
2Productivity
If anti-CD3 monoclonal antibody based strategies are used to activate and expand T cells, then the expansion efficiency is improved, but the enrichment for antigen-specific T cell responses is reduced
Solution Approach 1:
The patent applies local quality by designing the anti-CD3 monoclonal antibody to recognize a specific local epitope that includes the Fc region. This localized recognition pattern creates self-crosslinks at the antibody-T cell interface, concentrating activation signals precisely where needed while maintaining antigen specificity through the peptide-MHC complex requirement, thus achieving both high expansion efficiency and antigen-specific enrichment
3Manufacturing precision
If repeated weekly stimulations with peptide-loaded magnetic beads are used to enrich antigen-specific T cells, then the enrichment for antigen-specific responses is improved, but the time required increases to more than 2 months
Solution Approach 1:
The patent implements continuity of useful action by using a modified anti-CD3 monoclonal antibody that provides continuous activation signaling through self-crosslinking. Unlike discrete weekly stimulations, this approach maintains constant T cell activation and proliferation signals throughout the culture period, enabling rapid enrichment and expansion of antigen-specific T cells in 2-3 weeks rather than requiring prolonged repeated stimulations
Data Source
AI summary
Single chain trimer (SCT) molecules are disclosed, comprising an MHC antigen peptide sequence, a β2-microglobulin sequence and a full-length MHC class I heavy chain sequence, joined by linker sequences. Further described are nucleic acids encoding single chain trimers. Methods for expansion of antigen-specific T cell populations using single chain trimer molecules are also disclosed. In some configurations, these methods comprise co-culturing, in a first stage, CD8+ T cells from a donor with antigen presenting cells comprising an MHC antigen peptide, and co-culturing, in a second stage, the CD8+ T cells with cells comprising an SCT which has an MHC antigen peptide sequence identical to the sequence of the antigen peptide in the first stage. The methods can provide 10,000-100,000 fold expansion of antigen-specific CD8+ T cells within about 28 days after establishing culture, and can yield over 1 billion antigen-specific CD8+ T cells expanded from an individual donor.